Skip to content

Effects of Whole Body Vibration on Autonomic Function in Healthy Young and Elderly

Acute Effects of Whole Body Vibration on Autonomic Function in Healthy Young and Elderly

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03180814
Enrollment
35
Registered
2017-06-08
Start date
2017-07-31
Completion date
2017-12-30
Last updated
2018-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Healthy

Brief summary

Aging causes anatomical and physiological changes in the cardiovascular system and autonomic function with decline in its maximum function. This study aimed to evaluate the acute effects of whole body vibration on cardiovascular system, autonomic function and heart variability in healthy young and elderly. The investigators' hypothesis is that whole body vibration has different effects in young and elderly.

Interventions

OTHERWhole Body Vibration

A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.

Sponsors

Universidade Federal de Pernambuco
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Elderly individuals aged between 60 and 80 years * Young individuals aged between 18 and 30 years * Able to walk without assistance * Good understanding to perform the proposed procedures * Sedentary or low active

Exclusion criteria

* Body Mass Index (BMI) \> 35Kg/m2 * Systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg (at rest) * Difficulty adapting to the whole body vibration * Smoking * Neuromuscular or degenerative disorders * Neurological diseases * Cardiopulmonary comorbidities * Cardiac arrhythmias * Osteoarticular disorders * Use of hormone replacement therapy * Use medications or supplements known to affect cardiovascular parameters * Labyrinthitis

Design outcomes

Primary

MeasureTime frameDescription
Autonomic FunctionChange from Baseline Heart rate variability at 5, 10, 15, 20 and 35 minutesHeart rate variability will be assessed from 3-channel holter

Secondary

MeasureTime frameDescription
Parasympathetic modulationChange from Baseline Parasympathetic modulation at 5, 10, 15, 20 and 35 minutesParasympathetic modulation will be assessed from 3-channel holter
Sympathovagal BalanceChange from Baseline Sympathovagal balance at 5, 10, 15, 20 and 35 minutesSympathovagal Balance will be assessed from 3-channel holter
Heart RateChange from Baseline Heart Rate at 5, 10, 15, 20 and 35 minutesNon-invasive measures will be assessed from 3-channel holter
Sympathetic modulationChange from Baseline Sympathetic modulation at 5, 10, 15, 20 and 35 minutesSympathetic modulation will be assessed from 3-channel holter
Peripheral oxygen saturationChange from Baseline Peripheral oxygen saturation at 5, 10, 15, 20 and 35 minutesNon-invasive measures will be assessed from pulse oximeter
Adverse effectsChange from Baseline at 20 minutesAdverse effects reported by volunteers
Blood pressureChange from Baseline Blood pressure at 5, 10, 15, 20 and 35 minutesNon-invasive measures of brachial blood pressure

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026